Although MDM2 inhibitors exhibit a significant cytotoxic effect on the majority of TP53WT CLL primary samples, an intermediate response or resistance to RG7388 treatment in a small subset of TP53WT CLL samples (Figure 4B) emerged as an important finding that should be further investigated. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.